Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-14P stands for "RNA U6 small nuclear 14, pseudogene". It is annotated as a pseudogene related to the U6 small nuclear RNA (snRNA) family, specifically the 14th member of these pseudogenes. U6 snRNA genes code for the RNA component of the spliceosome, a nuclear complex essential for pre-mRNA splicing[1][3][4].\nHowever, RNU6-14P is a **pseudogene**, meaning it does not produce a functional RNA and is generally considered non-coding and non-functional. Pseudogenes like RNU6-14P are the result of retrotransposition or genomic duplication followed by loss of function. They are not considered therapeutic targets, are not druggable, and have no biomarker utility or direct disease association[3].\nThe **canonical, functional version** of this molecule would be the U6 small nuclear RNA (RNU6-1 or related functional U6 genes), which play an essential role as part of the major spliceosome in splicing pre-mRNA[1][4]. Pseudogenes like RNU6-14P are not the active RNAs, do not perform a biological function, and are not targets for therapy or diagnostics.\nIf you are interested in a therapeutic target, the relevant entity would be the U6 small nuclear RNA, not the RNU6-14P pseudogene.\n\n- **Canonical references for U6 snRNA function:**\n - U6 snRNA is a central component in spliceosome assembly and catalysis, coordinating magnesium ions and positioning pre-mRNA for splicing reactions[1][4].\n - Pseudogenes such as RNU6-14P are numerous throughout the genome; they are markers of genome evolution and retrotransposition but lack function[3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA U6 small nuclear 14, pseudogene (RNU6-14P).